Drug Trial Radar · NCT04991935
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
367
Actual
Start
Aug 9, 2022
Primary completion
Aug 14, 2025
Study completion Aug 14, 2025
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Conditions
- Eosinophilic Esophagitis
Interventions
CC-93538Drug
CC-93538
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: From first dose until study completion, early discontinuation, or loss of follow up, whichever occurs first (Up to approximately 36 months)
- Number of Participants With Clinically Significant Maximum Post Baseline Shifts in Laboratory ParametersTime frame: From first dose until study completion, early discontinuation, or loss of follow up, whichever occurs first (Up to approximately 36 months)
- Number of Participants With Clinically Meaningful Mean Changes in Vital Signs and Physical ParametersTime frame: From first dose until study completion, early discontinuation, or loss of follow up, whichever occurs first (Up to approximately 36 months)
Locations
167 sites in 15 countries. Site status is shown where the registry gives one.
Local Institution - 144
Birmingham, Alabama
Local Institution - 082
Phoenix, Arizona
Local Institution - 147
Phoenix, Arizona
Local Institution - 041
Scottsdale, Arizona
Local Institution - 029
Tucson, Arizona
Local Institution - 165
North Little Rock, Arkansas
Local Institution - 075
Lancaster, California
Local Institution - 047
Los Angeles, California
Local Institution - 160
San Diego, California
Local Institution - 068
Aurora, Colorado
Local Institution - 067
Colorado Springs, Colorado
Local Institution - 128
Wheat Ridge, Colorado
Local Institution - 101
Bristol, Connecticut
Local Institution - 076
Farmington, Connecticut
Local Institution - 156
Hamden, Connecticut
Local Institution - 099
Clearwater, Florida
Local Institution - 036
Inverness, Florida
Local Institution - 042
Jacksonville, Florida
Local Institution - 138
Miami, Florida
Local Institution - 146
Orlando, Florida
Local Institution - 169
Pinellas Park, Florida
Local Institution - 168
Plantation, Florida
Local Institution - 037
Port Orange, Florida
Local Institution - 171
Atlanta, Georgia
Local Institution - 054
Atlanta, Georgia
Local Institution - 117
Macon, Georgia
Local Institution - 024
Idaho Falls, Idaho
Local Institution - 039
Chicago, Illinois
Local Institution - 167
Gurnee, Illinois
Local Institution - 127
Clive, Iowa
Local Institution - 094
Iowa City, Iowa
Local Institution - 035
Kansas City, Kansas
Local Institution - 046
Florence, Kentucky
Local Institution - 003
Baton Rouge, Louisiana
Local Institution - 020
Metairie, Louisiana
Local Institution - 044
Metairie, Louisiana
Local Institution - 164
Columbia, Maryland
Local Institution - 070
Glen Burnie, Maryland
Local Institution - 012
Hagerstown, Maryland
Local Institution - 053
Boston, Massachusetts
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.